68Ga-NOTA-杜拉霉素PET/CT显像在淋巴瘤患者早期疗效评估中的潜在作用:一例病例报告
本文报告一例50岁男性活检证实的弥漫性大B细胞淋巴瘤患者,计划接受蒽环类化疗,在化疗2周期前后分别行68Ga-NOTA-杜拉霉素PET/CT及18F-FDG PET/CT显像; interim 68Ga-NOTA-杜拉霉素PET/CT的示踪剂亲和力显示出评估化疗早期疗效的诊断潜力。
要点
- 68Ga-NOTA-杜拉霉素可靶向凋亡细胞外露的磷脂酰乙醇胺。
- 病例为50岁男性弥漫性大B细胞淋巴瘤,计划蒽环类化疗。
- 化疗2周期前后行68Ga-NOTA-杜拉霉素及18F-FDG PET/CT, interim杜拉霉素显像示早期疗效评估潜力。
核心结论
- interim 68Ga-NOTA-杜拉霉素PET/CT的示踪剂亲和力显示出评估化疗早期疗效的诊断潜力。
研究设计与样本
- 病例报告:一例50岁男性活检证实的弥漫性大B细胞淋巴瘤患者,计划接受蒽环类化疗。
主要发现
- 在化疗2周期前后分别行68Ga-NOTA-杜拉霉素PET/CT及18F-FDG PET/CT显像, interim 68Ga-NOTA-杜拉霉素PET/CT的示踪剂亲和力显示出评估化疗早期疗效的诊断潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duramycin, a 19 amino acids peptide, is known for its potential to target phosphatidylethanolamine. During cell death (apoptosis), rearrangement of membrane phospholipids results in the externalization of phosphatidylethanolamine to the outer leaflet of the cell membrane, which can be imaged using 68Ga-NOTA-duramycin. We report 68Ga-NOTA-duramycin imaging in a 50-year-old man with biopsy-proven diffuse large B-cell lymphoma planned for anthracycline-based chemotherapy. 68Ga-NOTA-duramycin PET/CT imaging along with 18F-FDG PET/CT was performed before and after 2 cycles of chemotherapy. The tracer avidity in interim 68Ga-NOTA-duramycin PET/CT showed its diagnostic potential to assess early response to chemotherapy.
引用
- Kaur G, Shukla J, Sood A, et al. Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report. Clin Nucl Med. 2022. PMID: 36469075. doi:10.1097/RLU.0000000000004462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。